Schrödinger

Schrödinger reports rising demand for its physics-based drug discovery platform: annualized contract value rose 27% in Q2 and revenue in the first half increased 19%. The share of hosted software revenue reached 47%, exceeding the three-year target and indicating the cloud migration is progressing faster than expected. New product Bunsen is attracting particularly strong customer interest, with all 20 leading pharma companies among its customers. Schrödinger is targeting adjusted EBITDA break-even by 2028 and is using spin-offs, upfront payments and cost discipline to improve profitability. » Altro su de.investing.com

Schrödinger reported an adjusted Q2 2026 EPS of $0.08 versus an expected -$0.49 and revenue of $58.9 million versus an estimated $48.08 million. Annual contract value (ACV) rose 27% to $29.6 million, and the hosted software model accounted for 47% of software revenue. The company raised its full-year guidance for the drug discovery business to $65–75 million after a $10 million milestone payment from Ajax. The stock rose after the results, and Schrödinger emphasized long-term growth potential from new products like Bunsen and Predictive Tox despite near-term margin pressure. » Altro su de.investing.com

Schrödinger and Bristol Myers Squibb are expanding their partnership: BMS will use Schrödinger’s AI platform Bunsen together with the computational platform and the synthesis‑planning software RetroSynth in research. Schrödinger is working with BMS scientists to further develop Bunsen for large‑scale chemical exploration and the integration of physics‑based calculations. The goal is to plan, execute and interpret workflows in molecular research to speed up the discovery of new drugs. » Altro su de.investing.com